Who is affected by this change?

This affects Independence Blue Cross Endocrinology, Pediatrics, Neurology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 1, 2026.

Back to dashboard

Medicare AdvantageCoverageLow impact

MA08.154a, olipudase alfa-rpcp (Xenpozyme®)

Independence Blue Cross·Endocrinology, Pediatrics, Neurology·Pharmacy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.154a for olipudase alfa-rpcp (Xenpozyme®) has been reissued with an effective date of April 1, 2026. This is a pharmacy policy update that affects coverage or billing requirements for this rare disease medication used to treat acid sphingomyelinase deficiency.

Action Required

Action needed

By April 1, 2026: Review updated policy MA08.154a for olipudase alfa-rpcp (Xenpozyme®) coverage requirements. Billing team should access the full policy at the provided URL to understand any changes to prior authorization, documentation, or billing procedures for this medication. Update billing protocols accordingly.

Related policy hubs

Independence Blue Cross policies Endocrinology Pediatrics Neurology